See the full story in the original article.
Read the original on Yahoo Finance ↗
Related news
- Rocket Lab Tumbles 11% as Neutron’s First Flight Moves to 2027; SpaceX and AST SpaceMobile Pull Back
Rocket Lab said the first launch of its Neutron rocket is now expected in 2027, after manufacturing found voids in the carbon composite layers of the propellant dome. CEO Peter Beck said the problem is solved and would reduce margin but not necessarily cause an in-flight failure, while cryogenic and hydrostatic testing will not finish until Q1 2027, later than the earlier target of delivering Neutron to the launch pad before the end of 2026. Rocket Lab shares fell 11% to $52.85 in morning trading, after an 8% drop the previous day to $59.18. SpaceX and AST SpaceMobile each fell about 2%, the UFO ETF slid 2% and the SPY fell 0.3%, which the article reads as a company-specific repricing. Backlog reached $2.36 billion at the end of Q2 2026, up 137% year over year.
- AST SpaceMobile Falls 8% as Piper Sandler Cuts Target to $54 on SpaceX Competition; Rocket Lab Slips
Piper Sandler downgraded AST SpaceMobile to Neutral from Overweight and cut its price target to $54, citing lower confidence in the company's satellite launch pace over the next two years. The firm pointed to SpaceX's expanding direct-to-cell plans, warning SpaceX could limit launch availability for partners or pressure pricing through its own service. Clear Street reiterated a Buy rating and $115 target, arguing AST SpaceMobile remains roughly six months ahead of SpaceX in direct-to-cell. Three more BlueBird satellites arrived at Cape Canaveral ahead of a planned launch, but no firm date has been set. AST SpaceMobile shares fell 8% to $43.38, a steeper drop than Rocket Lab (down 2% to $62.77) and SpaceX (down 2% to $152.88).
- AST SpaceMobile’s stock is feeling the heat from SpaceX’s wireless plans
- Why AST SpaceMobile Stock Keeps Falling
AST SpaceMobile (ASTS) rose 1% on Monday before falling again on Tuesday, down about 9% intraday and nearly 26% over the past week. Deutsche Bank upgraded the stock to buy after it lost 65% of its market capitalization from May to October, arguing investors overreacted to launch delays; analyst Bryan Kraft says all but $10 of the share price is backed by the value of AST's cellphone spectrum. Kraft also expects SpaceX's satellite direct-to-cell network to push telecom companies toward partnering with AST. Piper Sandler downgraded the stock to neutral, noting that Ariane, Blue Origin and United Launch Alliance rockets are currently unavailable, which leaves AST dependent on SpaceX, now its primary competitor, to launch satellites. AST needs between 45 and 60 satellites to cover even select markets.
- AST SpaceMobile Sinks 9% as Piper Sandler Cuts to Neutral on SpaceX Direct-to-Cell Threat; Planet Labs Drops 4%, Rocket Lab Slips
AST SpaceMobile (ASTS) fell 9% to $46.58 in morning trading after Piper Sandler downgraded the stock to Neutral from Overweight, citing less conviction in the pace of commercial satellite launches, as SpaceX's expanding direct-to-cell push could restrict launch access and pressure pricing. The stock is down 36% year to date and below its prior 52-week low of $47.57. Deutsche Bank took the opposite view in the previous session, upgrading to Buy from Hold and arguing the selloff exceeded the value of the company's spectrum position. Planet Labs (PL) and Rocket Lab (RKLB) also declined, down 4% and 2%. AST SpaceMobile has 13 BlueBird satellites in orbit, targets 45 by early 2027, and reports a contracted backlog of $1.3 billion.
- AST SpaceMobile Stock Price Target Slashed in Half. The SpaceX Curse.
Related markets
Latest news
- One of this year's most important relationships in global financial markets is falling apart
One of the most important relationships in global markets has started to unravel over the past couple of weeks. Investors are scrambling to work out what it could mean for the economy and their portfolios.
- 2 High-Flying Dividend Stocks to Buy and Hold for a Decade
The article argues healthcare is rebounding in 2026, with Merck (MRK) shares up 39% and AbbVie (ABBV) up 24% year to date, versus about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating estimates, with Keytruda sales of $8.4 billion, though Keytruda may lose patent exclusivity by 2028. AbbVie's second-quarter revenue grew 10.2% to nearly $17 billion and adjusted EPS rose 22.9% to $3.65, driven by Skyrizi and Rinvoq sales growing about 24%. AbbVie is on a streak of 54 consecutive annual dividend increases, including its time as part of Abbott Laboratories, qualifying it as a Dividend King. The author concludes both are attractive long-term holdings based on financial results, pipelines, and dividends.
- Nvidia (NVDA) Stock Price Lags Massive Earnings Growth—A Compelling Value Opportunity
Munro Partners' Munro Global Growth Fund posted a -12.6% net return in Q3 2026, trailing the MAET.ASX return of -13.8%, with long holdings the main detractors. The fund's letter named NVIDIA (NASDAQ:NVDA) its largest contributor, citing strong earnings growth and guidance for at least 70% revenue growth next fiscal year, versus consensus of 45%. Nvidia reported quarterly revenue of USD96.2bn in August, up 106% year on year, and management said growth would have been closer to 100% without supply constraints. As of October 12, 2026, NVDA closed at $214.13, down 4.23% over the past month and up 19.23% over the past year, with a $5.16 trillion market cap and a 52-week range of $164.27 to $243.37. The fund says demand for semiconductors and AI remains strong, creating a constructive setup as capex and political fears are now priced in.
- Better Artificial Intelligence Stock for 2026: C3.ai vs. SentinelOne
The article compares C3.ai, which sells enterprise AI applications, with SentinelOne, which provides AI-powered autonomous cybersecurity. In fiscal 2026 (ended April 30), C3.ai's revenue was nearly $250.3 million, down 35.7%, with a net loss of $470.4 million and negative free cash flow of $190.7 million. SentinelOne's fiscal 2026 (ended January 31) revenue reached $1.0 billion, up 21.9%, with a net loss of $450.7 million and free cash flow of about $75.9 million, though stock-based compensation equaled roughly 388.4% of operating cash flow. The article cites C3.ai's restructuring plan from February 2026 and long government sales cycles as risks, and SentinelOne's competition from larger vendors and reliance on Amazon hosting. It says SentinelOne trades at a lower valuation relative to sales, while C3.ai has no future earnings estimates.
- Salazar Resources to Begin Drilling the Yumi Gold-Silver Veins at Tarqui, with Porphyry Drilling Planned at Monja, Ecuador
Salazar Resources closed a $3,500,000 non-brokered private placement announced on October 8, 2026, and outlined its exploration plan. Phase 1 is about 1,500 metres of drilling in five holes at the Yumi gold-silver veins on its 100%-owned Tarqui project, with drilling expected to begin in late October 2026, and the veins have not previously been drilled. Selective rock-chip samples returned 105 g/t Au and 1,038 g/t Ag, and historical BHP holes intersected porphyry-style mineralization nearby, which the company interprets as lying on the periphery of a porphyry center not yet located. Phase 2 contemplates up to about 3,500 metres of drilling in four holes at the 100%-owned Monja copper-gold porphyry target from the first quarter of 2027, subject to surface access and permits. A soil survey of about 895 samples is also planned at Quimi, part of the Tarqui-Quimi project.
- Musk: AI’s Hard Part Is “Scaling Power”: 3 Stocks Uniquely Suited to Win This New Bottleneck Trade
Microsoft said it will scale its Maia chips to multi-gigawatt deployments starting next calendar year, and Elon Musk said scaling power is the hard part of AI. The article argues power is an input that chip and app companies cannot copy quickly, which favors Vistra (VST), Constellation Energy (CEG) and GE Vernova (GEV). Vistra has lost nearly a fifth of its value over the past year even though its adjusted EBITDA rose to $5.91 billion, while Constellation's normalized EPS is expected to reach $13.29 in fiscal 2027. GE Vernova's revenue is expected to reach $60.7 billion by fiscal 2028, and Jefferies has a $298 price target on Vistra. The article warns that all three stocks could move with the mood around AI, regardless of their results.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.